MYH9 knockdown and MYH9 inhibitor, Blebbistatin, displayed anti-tumor effects in DLBCL through inhibiting cell proliferation and viability (Fig. 5F and G), inducing cell cycle arrest (Fig. 5H), promoting cell apoptosis (Fig. 5I), and decreasing cell invasion (Fig. 5J). Here, MYH9 is linked to diffuse large B-cell lymphoma.